Comparison of urine cell characteristics by flow cytometry and cytology in patients suspected of having bladder cancer

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 8, 2002, Pages 817-823

  Barlandas Rendón, Eric ^a   Müller, Mathias M ^a   García Latorre, Ethel ^a   Heinschink, Angelika ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Bladder cancer; CD 45; Cytokeratin; Cytology; DNA index; Flow cytometry

Indexed keywords

CD45 ANTIGEN; CYTOKERATIN; DNA; KERATIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CELL CYCLE G2 PHASE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MITOSIS; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; URINALYSIS; BLADDER TUMOR; COMPARATIVE STUDY; MIDDLE AGED; PLOIDY; REPRODUCIBILITY; STANDARD; URINE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD45; CYTOLOGICAL TECHNIQUES; DNA; FEMALE; FLOW CYTOMETRY; HUMANS; KERATINS; MALE; MIDDLE AGED; PLOIDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 0036379244     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.142     Document Type: Article

References (40)

1. Rath GD. Bladder cancer, 1992. Postgrad Med 1992; 92:105-22.
2. Kryger JV, Messing E. Bladder cancer screening. Semin Oncol 1996; 23:585-97.
3. Geller AC, Brooks DR, Barber CE, Koh HK, Lew RA, Wax S, Prout NM. Advances in screening protocols for the detection of early bladder cancer. J Occup Med 1990; 32:929-33.
4. Lauricica R, Schwartz RM. Clinical utility of flow cytometry in body fluid cytology. Diag Cytopathol 2001; 24:305-6.
5. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985; 29:810-5.
6. Koss LG. Cytology accuracy of diagnosis. Cancer 1989; 64(Suppl):249-52.
7. Nenning H, Raßler J, Minh DH, Stolzenburg JU. The value of DNA cytometry in transitional cell carcinoma of the urinary bladder. Gen Diagn Pathol 1997; 143:231-6.
8. Melamed MR. Flow cytometry detection and evaluation of bladder tumors. J Occup Med 1990; 32:829-33.
9. Feitz WFJ, Beck HLM, Smeets AWGB, Debryune FMJ, Vooijs GP, Herman CJ, et al. Tissue-specific markers in flow cytometry of urological cancers: cytokeratins in bladder carcinoma. Int J Cancer 1985; 36:349-56.
10. Huffman JL, Garin-Chesa P, Gay H, Whitmore WF, Melamed MR. Flow cytometric identification of human bladder cells using a cytokeratin monoclonal antibody. Ann NY Acad Sci 1986; 368:302-15.
11. Sánchez-Carbayo M, Ciudad J, Urrutia M, Navajo JA, Orfao A. Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma. Cancer 2001; 92:2811-9.
12. Zarbo JR, Brown DR, Linden DM, Torres XF, Nakhleh ER, Schultz SD. Rapid (one-shot) staining for two-color multiparametric DNA flow cytometric analysis of carcinomas using staining for cytokeratin and leukocyte common antigen. Am J Clin Pathol 1994; 11:391-402.
13. Smeets AWGB, Pauwels RPE, Beck HLM, Geraedts JPM, Debruyne FMJ, Laarakkers L, et al. Tissue-specific markers in flow cytometry of urological cancers III. Comparing chromosomal and flow cytometric DNA analysis of bladder tumors. Int J Cancer 1987; 39:304-10.
14. Ramaekers FCS, Beck HLM, Vooijs GP, Herman CJ. Flow-cytometric analysis of mixed cell populations using intermediate filament antibodies. Exp Cell Res 1984; 153:249-53.
15. Hijazi A, Devonec M, Bouvier R, Revillard JP. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors. J Urol 1989; 141:522-5.
16. Konchuba AM, Clements MC, Schellhammer PF, Schlossberg SM, Wright GL. Failure of anticytokeratin 18 antibody to improve flow cytometric detection of bladder cancer. Cancer 1992; 70:2879-84.
17. Melamed MR. Flow cytometry for detection and evaluation of urinary bladder carcinoma. Semin Surg Oncol 1992; 8:300-7.
18. Deitch AD, Andreotti VA, Strand MA, Howell LP, deVere White RW. A clinically applicable method to preserve urine and bladder washing cells for flow cytometric monitoring of bladder cancer patients. J Urol 1990; 143:700-5.
19. Howell LP, Westrick LA, Deitch AD, deVere White RW, Andreotti VA. Fixation method useful for cytologic examination and DNA flow cytometry of exfoliated bladder cells. Urology 1993; 41:472-5.
20. Klein FA, White FKH. Flow cytometry deoxyribonucleic acid determinations and cytology of bladder washing, practical experience. J Urol 1988; 139:275.
21. Vindeløov LL, Christensen IJ, Engelholm SA, Guldhammer BH, Høojgaard K, Søorensen BL, et al. Prognostic significance of DNA content in bladder cancer based on flow cytometry analysis of 249 transitional cell carcinomas. Cytometry 1995; 22:93-102.
22. Koss LG. Diagnostic cytology and its histopathologic bases, 4th ed. Philadelphia: Lippincott-Raven; 1992:890-1017.
23. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22:1435-48.
24. Murphy WM. Bladder cancer redefined. Cancer 1999; 86:1980-2.
25. Wolinska WH, Melamed MR, Klein FA. Cytology of bladder papilloma. Acta Cytol 1985; 29:817-22.
26. Robinson JP, editor. Handbook of flow cytometry methods, 1st ed. New York: Wiley-Liss, 1993:20pp.
27. Mellon K, Shenton KB, Neal ED. Is voided urine suitable for flow cytometric DNA analysis?. Br J Urol 1991; 67:48-53.
28. Wheeless LL, Badalament, AR, deVere White RW, Fradet Y, Tribukait B. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 1993; 14:478-81.
29. http://www.bdfacs.com/sourceok/htlm/2345.shtml Dual-color staining for DNA analysis. Becton Dickinson procedures, accessed 22 Jan 2000.
30. Brown DR, Linden DM, Mackowiak P, Kubus JJ, Zarbo JR, Rabinovitch SP, et al. The effect of number of histogram events on reproducibility and variation of flow cytometric proliferation measurement. Am J Clin Pathol 1996; 105:696-704.
31. Murphy WM, Soloway MS, Jukkola AF. Urinary cytology and bladder cancer: the cellular features of transitional cell neoplasms. Cancer 1984; 53:1555-65.
32. Koss LG. Reporting urinary bladder specimens containing bladder neoplasm. Hum Pathol 1997; 28:389.
33. Murphy WM, Crissman JD, Johansson SL, Ayala AG. Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Hum Pathol 1996; 27:751-3.
34. Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumours, 5th ed. New York: Wiley-Liss, 1997:189pp.
35. De Vita R, Forte D, Maggi F, Eleuteri P, Di Silverio F. Cellular DNA content and proliferative activity evaluated by flow cytometry versus histopathological and staging classifications in human bladder tumors. Eur Urol 1991; 19:65-73.
36. Lipponen PK, Eskelinen MJ, Collan Y, Pesonen E, Ventilä T, Sotarauta M, et al. DNA ploidy and S phase fraction in human bladder cancer. Urol Int 1990; 45:4-9.
37. D'hautcourt J, Spyratos F, Chassevent A. Quality control study by the French Cytometry Association on flow cytometric DNA content and S-phase fraction (S%). Cytometry 1996; 26:32-9.
38. Solé M, Alós L, Mallofré C, Romero JA, Muntané J, Cardesa A. Bladder wash flow cytometry in transitional cell carcinoma: useful or misleading? Urol Res 1995; 22:361-5.
39. Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987; 60:1423-7
40. Hermansen DK, Badalament RA, Bretton PR, Kimmel M, Aswad CM, Whitmore WF, et al. Voided urine flow cytometry in screening high-risk patients for the presence of bladder cancer. J Occup Med 1990; 32:894-7.